Cancers, Vol. 11, Pages 1472: Current Perspectives in Cancer Immunotherapy

Cancers, Vol. 11, Pages 1472: Current Perspectives in Cancer Immunotherapy Cancers doi: 10.3390/cancers11101472 Authors: Theodoulakis Christofi Stavroula Baritaki Luca Falzone Massimo Libra Apostolos Zaravinos Different immunotherapeutic approaches have proved to be of significant clinical value to many patients with different types of advanced cancer. However, we need more precise immunotherapies and predictive biomarkers to increase the successful response rates. The advent of next generation sequencing technologies and their applications in immuno-oncology has helped us tremendously towards this aim. We are now moving towards the realization of personalized medicine, thus, significantly increasing our expectations for a more successful management of the disease. Here, we discuss the current immunotherapeutic approaches against cancer, including immune checkpoint blockade with an emphasis on anti-PD-L1 and anti-CTLA-4 monoclonal antibodies. We also analyze a growing list of other co-inhibitory and co-stimulatory markers and emphasize the mechanism of action of the principal pathway for each of these, as well as on drugs that either have been FDA-approved or are under clinical investigation. We further discuss recent advances in other immunotherapies, including cytokine therapy, adoptive cell transfer therapy and therapeutic vaccines. We finally discuss the modulation of gut microbiota composition and response to immunotherapy, as well as how tumor-intrinsic ...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research

Related Links:

ConclusionsUnlike [18F]FDG, [18F]BODIPY 1 showed prominent accumulation in BAT under both inactive and stimulated status. [18F]BODIPY 1 may serve as a valuable BAT PET agent to possibly assess BAT mitochondria density, thus BAT thermogenic capacity after further evaluation.
Source: Molecular Imaging and Biology - Category: Molecular Biology Source Type: research
ConclusionsHypoxia modulation may play a role in nal-IRI ’s mechanism of action. Nal-IRI demonstrated greater anti-tumor activity in the more aggressive and hypoxic tumor model. Furthermore, hypoxia imaging provided early prediction of treatment response.
Source: Molecular Imaging and Biology - Category: Molecular Biology Source Type: research
AbstractPurposeTo investigate and validate the potential role of a radiomics signature in predicting the side-specific probability of extracapsular extension (ECE) of prostate cancer (PCa).ProceduresThe preoperative magnetic resonance imaging data of 238 prostatic samples from 119 enrolled PCa patients were retrospectively assessed. The samples with were randomized in a two-to-one ratio into training (n = 74) and validation (n = 45) datasets. The radiomics features were derived from T2-weighted images (T2WIs). The optimal radiomics features were identified from the least absolute shrinkage and s...
Source: Molecular Imaging and Biology - Category: Molecular Biology Source Type: research
ConclusionsIntegrated [68Ga]PSMA-11 PET/MRI provides a similarly high diagnostic performance for localization of recurrent PC as PET/CT. For the detection of local recurrences [68Ga]PSMA-11 PET/MRI is superior compared with [68Ga]PSMA-11 PET/CT.
Source: Molecular Imaging and Biology - Category: Molecular Biology Source Type: research
Publication date: Available online 25 May 2020Source: Life SciencesAuthor(s): Serena L'Abbate, Ilaria Russo, Claudia Kusmic
Source: Life Sciences - Category: Biology Source Type: research
Dear colleagues, please advise concerning this patient: 40 yo male, high PS, diagnosed a couple of years ago of colic cancer that was locally treated. Aug 2020: he was diagnosed of left parietal (at the level of the motor strip) solitary brain lesion. octobre 2020: he underwent a complete resection , followed by cavity SRS 18Gy /1 fr April 2020: refractory seizures MRI showed a relapsing left parietal cavity lesion, whose epicenter was next to the trolard vein. he was re-resected quasi... re-irradiation after single fraction cavity SRS? What dose?
Source: Student Doctor Network - Category: Universities & Medical Training Authors: Tags: Radiation Oncology Source Type: forums
Publication date: Available online 12 May 2020Source: The Journal of Molecular DiagnosticsAuthor(s): Manny D. Bacolod, Aashiq H. Mirza, Jianmin Huang, Sarah F. Giardina, Philip B. Feinberg, Steven A. Soper, Francis Barany
Source: The Journal of Molecular Diagnostics - Category: Pathology Source Type: research
To observe the surgical index at the different learning stages of thoraco-laparoscopic esophagectomy in the prone position for esophageal cancer and to investigate the learning curve of this surgical procedure.
Source: Journal of Cardiothoracic Surgery - Category: Cardiovascular & Thoracic Surgery Authors: Tags: Research article Source Type: research
We report that the loss of 4.1N correlated with progress in clinical stage, as well as poor survival in EOC patients. The loss of 4.1N induces EMT in adherent EOC cells and its expression inhibits anoikis resistance and EMT by directly binding and accelerating the degradation of 14-3-3 in suspension EOC cells. Furthermore, the loss of 4.1N could increase the rate of entosis, which aggravates cell death resistance in suspension EOC cells. Moreover, xenograft tumors in nude mice also show that the loss of 4.1N can aggravate peritoneal dissemination of EOC cells. Single-agent and combination therapy with a ROCK inhibitor and ...
Source: Protein and Cell - Category: Cytology Tags: Protein Cell Source Type: research
Publication date: Available online 26 May 2020Source: Oral Surgery, Oral Medicine, Oral Pathology and Oral RadiologyAuthor(s): Radosław Mlak, Tomasz Powrózek, Anna Brzozowska, Iwona Homa-Mlak, Marcin Mazurek, Paweł Gołębiowski, Dorota Korzeb, Mansur Rahnama-Hezavah, Teresa Małecka-Massalska
Source: Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology - Category: ENT & OMF Source Type: research
More News: Allergy & Immunology | Cancer | Cancer & Oncology | Cancer Vaccines | Cytokine Therapy | Immunotherapy | Vaccines